Alchemia loss grows on lower fondaparinux sales

Alchemia's (ASX:ACL) share of the profits from sales of anti-coagulant generic fondaparinux declined in FY14, but the company expects business to pick up from 2015.


> Posted in Health & medical on 02 September, 2014

Australia's medical research sector advocates for the Medical Research Future Fund

The newly formed Medical Research Future Fund (MRFF) Action Group is advocating for what it claims to be the most important initiative in Australian medical research in... [+]

> Posted in Biotechnology on 02 September, 2014

AFL approves use of Regeneus's HiQCell

The AFL has added Regeneus (ASX:RGS) HiQCell to a list of approved treatments for injuries including impact-related osteoarthritis and tendonitis. [+]

> Posted in Biotechnology on 27 August, 2014

Vaxxas recognised by WEF for vaccine tech

Vaxxas has been selected as a 2015 Technology Pioneer by the World Economic Forum for its patch-based vaccine delivery technology.


> Posted in Biotechnology on 27 August, 2014

Imugene names Charles Walker as new CEO

Former Alchemia (ASX:ACL) chief Charles Walker has taken the role of Imugene (ASX:IMU) CEO, to help lead the company's efforts to commercialise HER-Vaxx in gastric... [+]

> Posted in Health & medical on 26 August, 2014

Latest News

Pharmaxis to take anti-inflammatory to human trials

Pharmaxis (ASX:PXS) plans to conduct the first human trials of PXS4728A - a drug candidate for... [+]

> Posted in Biotechnology

More funding for medical research

New treatments, improved research translation and Indigenous youth suicide are some of the areas... [+]

> Posted in Health & medical

Minomic forges prostate cancer partnership

Minomic International and US-based Catalent Pharma Solutions will jointly develop the former's... [+]

> Posted in Health & medical

PAP therapy saves lives in heart patients: ResMed

Positive airway pressure (PAP) therapy in heart patients with sleep apnoea can reduce... [+]

> Posted in Biotechnology

GI Dynamics lines up new CEO

Seasoned medical device executive Michael Dale will take over from Stuart A Randle as CEO of GI... [+]

> Posted in Biotechnology

Click here for your FREE subscription

Australian Life Scientist: The Magazine

The magazine for research professionals in the life science and biotech sector across Australia. Click for your FREE subscription